Quality Of Life of Hypertensive Patients on Different Types of Antihypertensive Medications
More than three quarter of the total death in the UAE is due to cardiovascular diseases. Health Related Quality of Life (HRQL) is a broad multidimensional concept that usually includes subjective evaluations of both positive and negative aspects of life. The aim of the study was to evaluate the quality of life for hypertensive patients using different types of antihypertensive medications. A cross-sectional, randomized study was conducted in Ajman and Sharjah, October 2012 to May 2013, using a self-completed questionnaire and SF-36 HRQL questionnaire by 150 hypertensive patients on different types of medications and 220 control subjects. Around 53.3% of hypertensive patients used a combination therapy of two medicines; 33% used Angiotensin receptor blockers (ARB) + Diuretics and 20% used the combination of B-blockers + Diuretics.
Only 6% of the patients used B-Blockers class for their treatment. Data were analyzed by SPSS. The mean values of Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (V), Social Functioning (SF), Role Emotional (RE), Mental Health (MH), Physical Components Summary (PCS), and Mental Components Summary (MCS) scores were 62.5, 62.9, 72.1, 62.1, 64.5, 76.7, 68.8, 66.2, 47.0, and 47.8, respectively. Patients who were using a combination therapy of Angiotensin receptors blockers (ARB) plus Diuretics had the highest score in all SF-36 scales compared to other medications. Patients who were using Calcium channel blockers (CCB) had the lowest self-reported health compared to other medications. There were no significant differences between using single therapy of Angiotensin converting enzyme inhibitors (ACEI) or Angiotensin receptors blockers (ARB) and using a combination therapy of B-blockers + Diuretics; they almost had the same scores on most of the scales. Less than half (35.3%) of medication users suffered side effects from their medications and the common side effects they experienced were nausea (1.3%) and cough (34%). Early recognition of participants with this chronic disease is important in clinical disease management and in participation in education and intervention programs aimed at improving their HRQL.
|Journal||IOSR Journal Of Pharmacy|